Form 4: Cadrenal CEO Sells Shares in Pre-Arranged Trades

Cadrenal Therapeutics' CEO and Chairman, Quang Pham, reported the sale of 5,029 shares of common stock in pre-scheduled transactions.

Summary

• Quang Pham, CEO and Chairman of Cadrenal Therapeutics, Inc. (CVKD), reported the sale of 5,029 shares of common stock.
• On August 27, 2025, 3,836 shares were sold at a weighted average price of $13.99 per share, with prices ranging from $13.99 to $14.03.
• On August 28, 2025, an additional 1,193 shares were sold at a weighted average price of $13.99 per share, with prices ranging from $13.99 to $14.04.
• These transactions were conducted pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.
• Following these sales, Mr. Pham directly beneficially owns 213,304 shares and indirectly owns 200,000 shares through The PVBQ Living Trust, where he is the Trustee and his child is the sole beneficiary.

Sentiment

Score: 4

Explanation: The sale of shares by a key insider, even under a 10b5-1 plan, generally indicates a neutral to slightly negative sentiment, as it removes shares from the insider's holdings. The pre-arranged nature mitigates the immediate negative signal but does not eliminate it entirely.

Negatives

• The CEO and Chairman, a 10% owner, sold a total of 5,029 shares of common stock. While these sales were pre-arranged under a Rule 10b5-1 plan, insider selling can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects or that the stock is fully valued.

Related Party Transactions

• Quang Pham, as Trustee of The PVBQ Living Trust, has sole voting and disposition power over 200,000 shares where his child is the sole beneficiary. This represents an indirect beneficial ownership by a related party.

Stakeholder Impact

• Shareholders: May interpret the insider sales as a signal regarding the company's valuation or future prospects, potentially leading to downward pressure on the stock price.

Key Dates

Recommendation

The sale of shares by the CEO and Chairman, even under a pre-arranged 10b5-1 plan, is generally viewed as a neutral to slightly negative signal. It suggests the insider is taking profits or managing personal liquidity, rather than indicating strong conviction in significant near-term upside. Without additional information on company performance or strategic developments, a 'hold' recommendation is prudent, advising investors to monitor future filings and company news for clearer directional signals.

Keywords

Cadrenal Therapeutics, CVKD, Quang Pham, Insider Trading, Form 4, Stock Sale, CEO, Chairman, 10b5-1 Plan